BioNTech SE (NASDAQ:BNTX) Stock Position Lifted by Capital World Investors

Capital World Investors increased its stake in BioNTech SE (NASDAQ:BNTX) by 0.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 943,116 shares of the company’s stock after purchasing an additional 4,369 shares during the quarter. Capital World Investors owned about 0.40% of BioNTech worth $87,002,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd lifted its stake in shares of BioNTech by 2.5% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock worth $492,000 after acquiring an additional 116 shares during the period. Covestor Ltd boosted its stake in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares in the last quarter. GAMMA Investing LLC boosted its stake in BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares in the last quarter. Arlington Capital Management Inc. increased its position in shares of BioNTech by 10.0% during the 1st quarter. Arlington Capital Management Inc. now owns 2,200 shares of the company’s stock valued at $203,000 after purchasing an additional 200 shares during the period. Finally, Midwest Professional Planners LTD. raised its stake in shares of BioNTech by 7.2% in the 1st quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock worth $293,000 after buying an additional 212 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

BNTX opened at $85.94 on Friday. The firm has a market capitalization of $20.43 billion, a P/E ratio of 171.88 and a beta of 0.23. The stock has a fifty day moving average of $89.32 and a 200-day moving average of $91.47. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12-month low of $78.02 and a 12-month high of $125.83.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.60). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The business had revenue of $203.69 million for the quarter, compared to analyst estimates of $589.96 million. Equities analysts forecast that BioNTech SE will post -2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BNTX shares. Evercore ISI began coverage on BioNTech in a research note on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price for the company. BMO Capital Markets lowered their price objective on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and set a $113.00 target price on shares of BioNTech in a research note on Wednesday, June 26th. Finally, TD Cowen lifted their price target on shares of BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $111.70.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.